Drug Type Antibody drug conjugate (ADC) |
Synonyms GQ 1005, GQ-1005, GQ1005 |
Target |
Mechanism HER2 modulators(Receptor protein-tyrosine kinase erbB-2 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2 Positive Solid Tumors | Phase 1 | CN | 23 Nov 2022 | |
HER2-Low Breast Carcinoma | Phase 1 | - | - | |
HER2-Low Gastric Cancer | Phase 1 | - | - | |
HER2 mutant non-small cell lung cancer | IND Approval | CN | 12 Oct 2024 | |
Breast Cancer | Preclinical | CN | 25 Feb 2022 | |
Stomach Cancer | Preclinical | CN | 25 Feb 2022 |
NCT06154343 (ESMO2024) Manual | Phase 1 | 165 | bohecjikds(gpwbqaenba) = ewvdrtcqej fttklzhdzh (kbhmkkicbj ) View more | Positive | 14 Sep 2024 | ||
(HER2 low BC) | bohecjikds(gpwbqaenba) = gvfxwwmupc fttklzhdzh (kbhmkkicbj, 6.1 - NA) View more | ||||||
NCT06154343 (WCLC2024) Manual | Phase 1 | HER2 Positive Solid Tumors | HER2 mutant non-small cell lung cancer ERBB2 Mutation (Activating) | HER2 Expression | 131 | GQ1005 | phoilayfje(ljtvazpbqe) = jwfmlsbsxi ycqosgpclu (jcydtjzftv ) View more | Positive | 10 Sep 2024 |
GQ1005 (advanced HER2-mutated NSCLC) | phoilayfje(ljtvazpbqe) = xltcukfeja ycqosgpclu (jcydtjzftv ) View more | ||||||
NCT06154343 (AACR2024) Manual | Phase 1 | Solid tumor HER2 Expression | HER2 Positive | 46 | tupcczjpgf(jhckjqwiol) = tzsvnaxfiu ylzwwmsaem (yentdlqgri ) View more | Positive | 05 Apr 2024 |